Sofpromed Revenue and Competitors
Estimated Revenue & Valuation
- Sofpromed's estimated annual revenue is currently $7.2M per year.
- Sofpromed's estimated revenue per employee is $201,000
Employee Data
- Sofpromed has 36 Employees.
Sofpromed's People
Name | Title | Email/Phone |
---|
Sofpromed Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $71M | 300 | -3% | N/A | N/A |
#2 | $668.1M | 3222 | 3% | $20M | N/A |
#3 | $5.3M | 46 | N/A | N/A | N/A |
#4 | $5.1M | 46 | -13% | $950K | N/A |
#5 | $1.7M | 23 | -4% | $30M | N/A |
#6 | $0.7M | 9 | N/A | N/A | N/A |
#7 | $0.7M | 9 | N/A | N/A | N/A |
#8 | $0.6M | 8 | N/A | N/A | N/A |
#9 | $2.5M | 25 | N/A | N/A | N/A |
#10 | $14.2M | 98 | N/A | N/A | N/A |
#11 | $5060M | 7612 | -20% | $6.9M | $22.5B |
#12 | $53.7M | 302 | 7% | $8M | N/A |
#13 | $3.8M | 33 | N/A | N/A | N/A |
#14 | $4.2M | 21 | N/A | N/A | N/A |
#15 | $7.6M | 58 | 32% | N/A | N/A |
#16 | $25.7M | 161 | N/A | N/A | N/A |
#17 | $1167M | 5806 | N/A | N/A | N/A |
#18 | $16.5M | 82 | N/A | N/A | N/A |
#19 | $12.7M | 91 | -9% | $17.2M | N/A |
#20 | N/A | 39 | N/A | N/A | N/A |
What Is Sofpromed?
N/A
Total Funding
36
Number of Employees
$7.2M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sofpromed News
2022-04-17 - Phase I IV Clinical Development Services Market Analysis 2022 to ...
... Inc., Synteract, ICBio CRO, Sofpromed, Profil, ICON Plc, Clinipace, OCT Clinical, EPS Group, Beijing Sun-novo Pharmaceutical Research,...
2022-04-06 - Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline
Thus, according to an estimate by Sofpromed, the average cost of a Phase 1 clinical trial for eventual approval by the U.S. Food and Drug...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.3M | 36 | 33% | N/A |
#2 | $4.9M | 42 | N/A | N/A |
#3 | N/A | 52 | 18% | N/A |
#4 | $4M | 52 | 8% | N/A |
#5 | $16M | 67 | N/A | N/A |